Illumina and Broad Clinical Labs usher in new era of drug discovery with collaboration to rapidly scale single-cell solutions

Longstanding partners bring together end-to-end workflows and leading CRISPRPerturb-seq technologies setting a standard for single-cell studies and enabling a 5billion single-cell atlas ecosystem within three yearsSAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in next-generation sequencing and array-based technologies, today announced a collaboration with Broad Clinical Labs to rapidly streamline and scale single-cell projects with cutting-edge tools and workflows. T ...